Anti-KAT3A / CBP antibody [CBP5I001] (ab50702)


  • Product nameAnti-KAT3A / CBP antibody [CBP5I001]
    See all KAT3A / CBP primary antibodies
  • Description
    Mouse monoclonal [CBP5I001] to KAT3A / CBP
  • Tested applicationsSuitable for: Dot Blot, IHC-P, WB, IP, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Recombinant CBP

  • Positive control
    • HeLa whole cell lysate; NIH3T3 whole cell lysate. IHC-P: Human pancreas FFPE tissue sections.



Our Abpromise guarantee covers the use of ab50702 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Dot Blot Use at an assay dependent concentration.
IHC-P Use a concentration of 10 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
WB 1/50 - 1/100. Predicted molecular weight: 265 kDa.
IP 1/30.
ICC/IF 1/5.


  • FunctionAcetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 coactivator. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1 in the presence of EP300.
  • Involvement in diseaseNote=Chromosomal aberrations involving CREBBP may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with MYST3/MOZ; translocation t(11;16)(q23;p13.3) with MLL/HRX; translocation t(10;16)(q22;p13) with MYST4/MORF. MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription.
    Defects in CREBBP are a cause of Rubinstein-Taybi syndrome type 1 (RSTS1) [MIM:180849]. RSTS1 is an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies.
  • Sequence similaritiesContains 1 bromo domain.
    Contains 1 KIX domain.
    Contains 2 TAZ-type zinc fingers.
    Contains 1 ZZ-type zinc finger.
  • DomainThe KIX domain mediates binding to HIV-1 Tat.
  • Post-translational
    Methylation of the KIX domain by CARM1 blocks association with CREB. This results in the blockade of CREB signaling, and in activation of apoptotic response.
    Phosphorylated upon DNA damage, probably by ATM or ATR.
    Sumoylation negatively regulates transcriptional activity via the recruitment of DAAX.
  • Cellular localizationCytoplasm. Nucleus. Recruited to nuclear bodies by SS18L1/CREST. In the presence of ALX1 relocalizes from the cytoplasm to the nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • CBP antibody
    • CBP_HUMAN antibody
    • CREB binding protein antibody
    • CREB-binding protein antibody
    • Crebbp antibody
    • Cyclic AMP responsive enhancer binding protein antibody
    • KAT3A antibody
    • RSTS antibody
    • RTS antibody
    • Rubinstein Taybi syndrome antibody
    see all

Anti-KAT3A / CBP antibody [CBP5I001] images

  • IHC image of KAT3A staining in human pancreas formalin fixed paraffin embedded tissue section, performed on a Leica Bond system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab50702, 10µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

  • Anti-KAT3A / CBP antibody [CBP5I001] (ab50702) at 1/30 dilution + RIPA lysate of HeLa cells at 500 µg

    Mouse IgG antibody at 1/2500 dilution

    Predicted band size : 265 kDa
  • Anti-KAT3A / CBP antibody [CBP5I001] (ab50702) at 1/50 dilution + NIH3T3 whole cell lysate at 50 µg

    Mouse IgG antibody at 1/2500 dilution

    Predicted band size : 265 kDa
  • Anti-KAT3A / CBP antibody [CBP5I001] (ab50702) at 1/100 dilution + HeLa whole cell lysate at 50 µg

    Mouse IgG antibody at 1/2500 dilution

    Predicted band size : 265 kDa
  • Staining of HeLa cell lysate with ab50702 at a dilution of 1/5 and Goat anti-mouse secondary at 1/200.

References for Anti-KAT3A / CBP antibody [CBP5I001] (ab50702)

This product has been referenced in:
  • Benedikt A  et al. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia 25:135-44 (2011). WB ; Human . Read more (PubMed: 21030982) »

See 1 Publication for this product

Product Wall

Thank you for submitting an Abreview for ab50702. As you may have noticed, your review has now been published on our website.

Since you obtained poor results using the antibody in an untested application, we would like to follow up on this to ...

Read More
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (bladder)
Specification bladder
Fixative Formaldehyde
Antigen retrieval step Heat mediated
Permeabilization No
Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 1% · Temperature: RT°C

Abcam user community

Verified customer

Submitted Oct 30 2012